Prenatal screening tests
- Panorama test helps to examine that the fetus in the womb does not have Down, Edwards or Patau syndrome, X-linked diseases (Klinefelter and Turner syndrome) or triploidy. The patient gets an answer in 14 days.
- The Panorama 22q11 test in addition to the aforementioned chromosomal disorders, provides information about the most common genetic disorder, DiGeorge syndrome. The patient receives the answer 14 days after the blood test.
- Panorama XP test in addition to the chromosome diseases above, gives information also about the five most frequent genetic diseases that cause mental disability. The patient gets an answer in 14 days.
- The PrenatalSafe Karyo Plus test is a safe and accurate screening test for chromosomal and genetic diseases based on a non-invasive prenatal examination of fetal extracellular DNA in the mother's blood, which can be performed from the tenth week of pregnancy. The PrenatalSafe Karyo Plus test allows the detection of Down, Edwards and Patau syndromes as well as other numerical and structural chromosomal pathologies that cannot be evaluated with the Panorama test. Test also allows the detection of 9 clinically significant microdeletions and pathologies of the sex chromosomes, which all significantly affect the health of the child, from the mother's venous blood.
- Determination of the fetal Rh factor from fetal blood. By performing this test, a Rh-negative woman can find out whether she is carrying a Rh-positive or Rh-negative fetus. The patient will receive the answer 14 days after the blood test. To determine the possibility of a Rh conflict, it is possible to determine the Rh status of the fetus from the 10th week of pregnancy based on the fetal DNA circulating in the mother's blood.
- GeneSafe Complete test finds about 29 different fetal single gene pathologies that can cause 44 different de novo and five hereditary genetic diseases that are not very often detectable on ultrasound and usually only appear in late pregnancy or the first years of life. The Vistara test requires a mother's venous blood test and a father's oral mucosa DNA test using a swab. The patient receives a response 21 days after the blood test.
- The GeneScreen Complete test is a genetic disease carrier screening test that allows you to find partners with a higher risk of having a genetically affected child together. The GeneScreen Complete test evaluates the carrier of an autosomal recessive or X-linked disease in a woman and/or her partner. Such gene mutations can cause 2,100 genetic diseases in their joint children, which cannot be detected by prenatal ultrasound or in the immediate postnatal period, as most manifest only in the first years of the child's life.
- The Fetal Double test, or very early ultrasound examination of fetal developmental defects, together with the KaryoPlus and GeneSafe Complete test at the 10th week of pregnancy, and the combination of these studies with the OSCAR test at the 13th week of pregnancy, is currently the most accurate combined prenatal screening for the early detection of fetal congenital developmental defects and chromosomal and genetic diseases.
- The Fetal Triple test is a modern and innovative screening tool for the first trimester of pregnancy. It combines the benefits of two non-invasive tests: a fetal cell-free DNA chromosomal screening and carrier screening for both parents. Additionally, it incorporates three advanced ultrasound examinations conducted at various stages of fetal development.
